• Explore /
  • Poster
  • / Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).

Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).

Abstract Poster

Authors

null

Nizar M. Tannir

The University of Texas MD Anderson Cancer Center, Houston, TX

Nizar M. Tannir , Thomas Powles , Bernard J. Escudier , Frede Donskov , Viktor Grünwald , Cora N. Sternberg , Manuela Schmidinger , Patrick Schoffski , Cezary Szczylik , Katriina Johanna Peltola , Dmitry Nosov , Bohuslav Melichar , Douglas O. Clary , Christian Scheffold , Robert J. Motzer , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01865747

Citation

J Clin Oncol 35, 2017 (suppl; abstr 4570)

DOI

10.1200/JCO.2017.35.15_suppl.4570

Abstract #

4570

Poster Bd #

248

Abstract Disclosures

Similar Posters

First Author: Frede Donskov

First Author: Ignacio Duran

First Author: Thomas Powles

First Author: Antoine Thiery-Vuillemin